Sanofi, AstraZeneca Express Optimism Over Phase III Infant RSV Results

The latest results from Sanofi and AstraZeneca's Phase III trial nirsevimab demonstrate the vaccine's ability to protect all infants from the respiratory syncytial virus (RSV) with a single dose.